Back to Stakeholders
Categories

2 domains / 4 areas / 2 specializations

Care Delivery & Psychedelic Facilitation
Care Delivery & Psychedelic Facilitation
Psychedelic Healthcare ImplementationHealth Economists
Government, Policy & Advocacy
Government, Policy & Advocacy
Public Sector Health & Drug GovernanceHealth Technology Assessment Agencies

National Institute for Health and Care Excellence (NICE)

UK HTA body issuing evidence and cost-effectiveness recommendations that influence medicine access.

Reimbursement & Market Access Snapshot

Health Economists

Service Model

HTA / Value Assessment Body

Jurisdiction

National

Coverage

1 country

Last Verified

Apr 8, 2026

Focus Areas

HTA Evidence AppraisalCost-Effectiveness ModelingCoverage Policy DesignFormulary & Access Criteria

Evidence Requirements

Clinical Efficacy EndpointsComparative EffectivenessCost-EffectivenessBudget Impact

Market Access Notes

NICE publishes technology appraisals and methods that shape NHS access pathways; this includes guidance relevant to esketamine in treatment-resistant depression.

Verification

Verified

Psychedelic Focus

Psychedelic-Adjacent Focus

Engagement Status

Active

Primary Access Link

Source Evidence

NICE TA854 - Esketamine nasal spray for treatment-resistant depression

https://www.nice.org.uk/guidance/ta854

NICE - Health technology evaluation process

https://www.nice.org.uk/process/pmg36/chapter/introduction-to-health-technology-evaluation

Quick Facts

Website
Visit